Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.

Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

BioSpace

Hello, and welcome to BioSpace is the weekly. I'm your host, Jeff Axt. We are just entering second quarter earnings season, so we'll preview some updates that we'll be looking out for there. Plus, Eli Lilly just handed the psychedelic space its greatest validation yet with a multi-billion dollar purchase of a Ty Beckley. We'll also provide some updates to the FDA's ongoing initiative to publish complete response letters. This is an effort that has faced legal questions. And finally, we'll

take a look at the latest biotechs looking to take advantage of the now wide open IPO window. Let's get started. Hi, guys. How are you doing? Anybody watch the World Cup final on Sunday? Hey, I started watching it at about five o'clock Eastern when I thought it would be the last five minutes of the game. I ended up watching it for an hour and a half, I think. Right. That extra time was pretty critical. And that's, of course, when all the excitement happened

after basically a stalemate, although all the momentum was in Spain's favor the whole time. Right. I saw a couple of awesome goal, not goals, sorry, they were blocked goals, a couple of awesome saves, which was which was pretty exciting. Yeah, that Argentine goalie did his job. That's for sure. Although Argentina didn't get any shots on goal, although I have questions about what defines a shot on goal. So I saw a couple of things I would have called shots, but they weren't being marked as such. So I don't know the details there. I'm not a I'm not a soccer super fan. I watch when World Cup comes around every four years.

Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.